Kalaris Therapeutics Inc (NASDAQ: KLRS) started the day on Wednesday, with a price increase of 20.32% at $10.42, before settling in for the price of $8.66 at the close. Taking a more long-term approach, KLRS posted a 52-week range of $2.14-$12.90.
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -6.86%. Meanwhile, its Annual Earning per share during the time was -6.86%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 68.62%. This publicly-traded company’s shares outstanding now amounts to $18.70 million, simultaneously with a float of $5.04 million. The organization now has a market capitalization sitting at $174.41 million. At the time of writing, stock’s 50-day Moving Average stood at $5.79, while the 200-day Moving Average is $5.00.
Kalaris Therapeutics Inc (KLRS) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Kalaris Therapeutics Inc’s current insider ownership accounts for 73.07%, in contrast to 7.83% institutional ownership. According to the most recent insider trade that took place on Mar 26 ’25, this organization’s Chief Accounting Officer sold 907 shares at the rate of 8.97, making the entire transaction reach 8,135 in total value, affecting insider ownership by 1,925.
Kalaris Therapeutics Inc (KLRS) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
Kalaris Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 68.62% and is forecasted to reach -2.18 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 47.33% through the next 5 years, which can be compared against the -6.86% growth it accomplished over the previous five years trading on the market.
Kalaris Therapeutics Inc (NASDAQ: KLRS) Trading Performance Indicators
Let’s observe the current performance indicators for Kalaris Therapeutics Inc (KLRS). It’s Quick Ratio in the last reported quarter now stands at 12.89. In the same vein, KLRS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -7.40, a figure that is expected to reach -0.62 in the next quarter, and analysts are predicting that it will be -2.18 at the market close of one year from today.
Technical Analysis of Kalaris Therapeutics Inc (KLRS)
If we take a close look at the recent performances of Kalaris Therapeutics Inc (NASDAQ: KLRS), its last 5-days Average volume was 0.25 million that shows progress from its year to date volume of 0.13 million. During the previous 9 days, stock’s Stochastic %D was recorded 89.73% While, its Average True Range was 84.94.
Raw Stochastic average of Kalaris Therapeutics Inc (KLRS) in the period of the previous 100 days is set at 93.67%, which indicates a major rise in contrast to 90.48% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 0.89 that was higher than 0.63 volatility it exhibited in the past 100-days period.
